About Allarity Therapeutics
Allarity Therapeutics (NASDAQ:ALLR) focuses on pioneering personalized medicine, primarily by developing drugs that target cancer treatment based on the individual's genetic makeup. The company's approach prioritizes the DRP® platform (Drug Response Predictor), a cutting-edge tool aiming to predict a patient’s response to a specific cancer therapy, thereby enhancing treatment efficacy and minimizing unnecessary exposure to potential side effects. Among its key projects are several promising oncology drugs in various stages of development, each selected for their potential to meet unmet medical needs in cancer care. Allarity’s objective is to revolutionize how cancer is treated, making therapy personal and more effective by aligning treatment strategies with genetic profiles, ultimately improving patient outcomes and quality of life.
Snapshot
Operations
Products and/or services of Allarity Therapeutics
- Stenoparib, an inhibitor targeting ovarian cancer through PARP inhibition, facilitating DNA damage in cancer cells.
- IXEMPRA® (Ixabepilone), a microtubule inhibitor for the treatment of metastatic breast cancer, offering an alternative in cases resistant to anthracyclines and taxanes.
- LiPlaCis®, a lipid-conjugated form of cisplatin, designed to increase drug delivery to tumors, reducing systemic toxicity, focusing on metastatic breast cancer and prostate cancer.
- 2X-111, a liposome-encapsulated doxorubicin aimed at glioblastoma and metastatic breast cancer, intended to pass through the blood-brain barrier.
Allarity Therapeutics executive team
- Mr. Thomas H. JensenFounder, CEO & Director
- Dr. Jeremy R. Graff Ph.D.President & Chief Development Officer
- Dr. Steen Meier Knudsen Ph.D.Founder & Chief Scientific Officer
- Mr. Jeffrey S. Ervin M.B.A.Chief Financial Officer
- Dr. Jose L. Iglesias M.D.Consultant Chief Medical Officer